Prevention of Alzheimer's disease

International Review of Psychiatry

Volumn 19, Issue 6, 2007, Pages 693-706

  Szekely, C A ^a   Breitner, J C S ^b   Zandi, P P ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ARUNDIC ACID; ASCORBIC ACID; CONJUGATED ESTROGEN; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; DIHYDROPYRIDINE; DONEPEZIL; ESTROGEN; FENOPROFEN; FLURBIPROFEN; GALANTAMINE; GESTAGEN; GINKGO BILOBA EXTRACT; HUPERZINE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MEDROXYPROGESTERONE; MEMANTINE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; POTASSIUM SPARING DIURETIC AGENT; RIVASTIGMINE; ROSIGLITAZONE; SULINDAC; TACRINE; TESTOSTERONE;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG WITHDRAWAL; ESTROGEN THERAPY; HUMAN; MEDITERRANEAN DIET; MONOTHERAPY; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SOCIAL PSYCHIATRY; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; DRUG THERAPY; HUMANS; IMMUNOTHERAPY; INSULIN RESISTANCE; PREVENTIVE HEALTH SERVICES; RISK FACTORS;

EID: 38749129683     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260701797944     Document Type: Review

References (176)

1. Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L. et al. (2003). Effects of rofecoxib or naproxen versus placebo on Alzheimer disease progression: A randomized controlled trial. JAMA, 289, 2819-2826.
2. Aisen, P. S., Schmeidler, J., & Pasinetti, G. M. (2002). Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology, 58, 1050-1054.
3. Anekonda, T. S. (2006). Resveratrol - A boon for treating Alzheimer's disease? Brain Res Brain Res Rev, 52, 316-326.
4. Asthana, S., Baker, L. D., Craft, S., Stanczyk, F. Z., Veith, R. C., Raskind, M. A. et al. (2001). High-dose estradiol improves cognition for women with AD: Results of a randomized study. Neurology, 57, 605-612.
5. Asthana, S., Craft, S., Baker, L. D., Raskind, M. A., Birnbaum, R. S., Lofgreen, C. P. et al. (1999). Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology, 24, 657-677.
6. Bai, D. L., Tang, X. C., & He, X. C. (2000). Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr Med Chem, 7, 355-374.
7. Ball, K., Berch, D. B., Helmers, K. F., Jobe, J. B., Leveck, M. D., Marsiske, M. et al. (2002). Effects of cognitive training interventions with older adults: A randomized controlled trial. JAMA, 288, 2271-2281.
8. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H. et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med, 6, 916-919.
9. Behl, C. (1999). Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches. Prog Neurobiol, 57, 301-323.
10. Berchtold, N. C., Chinn, G., Chou, M., Kesslak, J. P., & Cotman, C. W. (2005). Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience, 133, 853-861.
11. Beresford, S. A., Johnson, K. C., Ritenbaugh, C., Lasser, N. L., Snetselaar, L. G., Black, H. R. et al. (2006). Low-fat dietary pattern and risk of colorectal cancer: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA, 295, 643-654.
12. Berr, C., Richard, M. J., Roussel, A. M., & Bonithon-Kopp, C. (1998). Systemic oxidative stress and cognitive performance in the population-based EVA study. Etude du Vieillissement Arteriel. Free Radic Biol Med, 24, 1202-1208.
13. Black, S. E., Wilcock, G., Haworth, J., Hendrix, S., Zavitz, K., Binger, M. et al. (2005). A placebo-controlled, double-blind trial of the selective Abeta42-lowering agent Flurizan in patients with mild to moderate Alzheimer's disease: Efficacy, safety, and follow-on results. In Program No. 585.6. Washington, DC: Society for Neuroscience.
14. Bosch, J., Yusuf, S., Pogue, J., Sleight, P., Lonn, E., Rangoonwala, B. et al. (2002). Use of ramipril in preventing stroke: Double blind randomised trial. BMJ, 324, 699-702.
15. Bostom, A. G., Rosenberg, I. H., Silbershatz, H., Jacques, P. F., Selhub, J., D'Agostino, R. B. et al. (1999). Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study. Ann Intern Med, 131, 352-355.
16. Breitner, J. C., Gau, B. A., Welsh, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J. et al. (1994). Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology, 44, 227-232.
17. Breitner, J. C., & Zandi, P. P. (2003). Effects of estrogen plus progestin on risk of dementia. JAMA, 290, 1706-1707.
18. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K. et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med, 352, 1092-1102.
19. Brookmeyer, R., Gray, S., & Kawas, C. (1998). Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health, 88, 1337-1342.
20. Centers for Disease Control (2003). Public health and aging: Trends in aging - United States and worldwide. Morbidity and Mortality Weekly Report, 52, 101-106.
21. Cherrier, M. M., Matsumoto, A. M., Amory, J. K., Asthana, S., Bremner, W., Peskind, E. R. et al. (2005). Testosterone improves spatial memory in men with Alzheimer disease and cmild cognitive impairment. Neurology, 64, 2063-2068.
22. Christen, S., Jiang, Q., Shigenaga, M. K., & Ames, B. N. (2002). Analysis of plasma tocopherols alpha, gamma, and 5-nitro-gamma in rats with inflammation by HPLC coulometric detection. Journal of Lipid Research, 43, 1978-1985.
23. Clarke, R., Smith, A. D., Jobst, K. A., Refsum, H., Sutton, L., & Ueland, P. M. (1998). Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol, 55, 1449-1455.
24. ClinicalTrials.gov (2006a). A pilot study of curcumin and ginkgo for treating Alzheimer's disease; Baum L, Principal Investigator; sponsored by BUPA Foundation and Institute of Chinese Medicine of the Chinese University of Hong Kong. Accessed on 22 Mar 2006.
25. ClinicalTrials.gov (2006b). Curcumin in patients with mild to moderate Alzheimer's disease; Ringman J., Study Director; sponsored by John Douglas French Foundation and ISOA. Accessed on 15 Nov 2006.
26. ClinicalTrials.gov (2006c). Effects of ONO-2506PO in patients with Alzheimer's disease. Accessed on 22 Dec 2006.
27. ClinicalTrials.gov (2006d). Huperzine A in Alzheimer's disease. Accessed on 23 Nov 2006.
28. ClinicalTrials.gov (2006e). Search 'rosiglitazone and Alzheimer'. Accessed on 23 Nov 2006.
29. Colcombe, S., & Kramer, A. F. (2003). Fitness effects on the cognitive function of older adults: A meta-analytic study. Psychol Sci, 14, 125-130.
30. Commenges, D., Scotet, V., Renaud, S., Jacqmin-Gadda, H., Barberger-Gateau, P., & Dartigues, J. F. (2000). Intake of flavonoids and risk of dementia. Eur J Epidemiol, 16, 357-363.
31. Cornelius, C., Fastbom, J., Winblad, B., & Viitanen, M. (2004). Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology, 23, 135-143.
32. Corrada, M. M., Kawas, C. H., Hallfrisch, J., Muller, D., & Brookmeyer, R. (2006). Reduced risk of Alzheimer's disease with high folate intake: The Baltimore Longitudinal Study of Aging. Alzheimer's and Dementia, 1, 11-18.
33. Cotman, C. W., & Berchtold, N. C. (2002). Exercise: A behavioral intervention to enhance brain health and plasticity. Trends Neurosci, 25, 295-301.
34. Craft, S. (2005). Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging, 26 Suppl 1, 65-69.
35. DeKosky, S. T., Fitzpatrick, A., Ives, D. G., Saxton, J., Williamson, J., Lopez, O. L. et al. (2006). The Ginkgo Evaluation of Memory (GEM) study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials, 27, 238-253.
36. DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De Putte, L. B. et al. (1998). Cyclooxygenase in biology and disease. FASEB J, 12, 1063-1073.
37. Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., van Swieten, J. C., Hofman, A., Witteman, J. C. et al. (2002). Dietary intake of antioxidants and risk of Alzheimer disease. JAMA, 287, 3223-3229.
38. Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C. et al. (2003). NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest, 112, 440-449.
39. Evans, D. A., Funkenstein, H. H., Albert, M. S., Scherr, P. A., Cook, N. R., Chown, M. J. et al. (1989). Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA, 262, 2551-2556.
40. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P. et al. (2001). Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA, 98, 5856-5861.
41. Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M. et al. (2005). Global prevalence of dementia: A Delphi consensus study. Lancet, 366, 2112-2117.
42. Fillenbaum, G. G., Kuchibhatla, M. N., Hanlon, J. T., Artz, M. B., Pieper, C. F., Schmader, K. E. et al. (2005). Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann Pharmacother, 39, 2009-2014.
43. Fishel, M. A., Watson, G. S., Montine, T.., Wang, Q., Green, P. S., Kulstad, J. J. et al. (2005). Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol, 62, 1539-1544.
44. Forette, F., Seux, M. L., Staessen, J. A., Thijs, L., Babarskiene, M. R., Babeanu, S. et al. (2002). The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med, 162, 2046-2052.
45. Forette, F., Seux, M. L., Staessen, J. A., Thijs, L., Birkenhager, W. H., Babarskiene, M. R. et al. (1998). Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet, 352, 1347-1351.
46. Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L. et al. (2005). Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology, 64, 1563-1572.
47. Fratiglioni, L., Paillard-Borg, S., & Winblad, B. (2004). An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol, 3, 343-353.
48. Gao, S., Hendrie, H. C., Hall, K. S., & Hui, S. (1998). The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. Arch Gen Psychiatry, 55, 809-815.
49. Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C. et al. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 64, 1553-1562.
50. Gold, P. E., Cahill, L., & Wenk, G. L. (2002). Ginkgo biloba: A cognitive enhancer? Psychological Science in the Public Interest, 3, 2-11.
51. Goodwin, J. S., Goodwin, J. M., & Garry, P. J. (1983). Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA, 249, 2917-2921.
52. Guallar, E., Hanley, D. F., & Miller III, E. R. III (2005). An editorial update: Annus horribilis for vitamin E. Ann Intern Med, 143, 143-145.
53. Guo, Z., Fratiglioni, L., Viitanen, M., Lannfelt, L., Basun, H., Fastbom, J. et al. (2001). Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: Variation by use of antihypertensive medication? Am J Epidemiol, 153, 225-231.
54. Guo, Z., Fratiglioni, L., Zhu, L., Fastbom, J., Winblad, B., & Viitanen, M. (1999). Occurrence and progression of dementia in a community population aged 75 years and older: Relationship of antihypertensive medication use. Arch Neurol, 56, 991-996.
55. Hajjar, I., Schumpert, J., Hirth, V., Wieland, D., & Eleazer, G. P. (2002). The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci, 57, M414-M418.
56. Harats, D., Chevion, S., Nahir, M., Norman, Y., Sagee, O., & Berry, E. M. (1998). Citrus fruit supplementation reduces lipoprotein oxidation in young men ingesting a diet high in saturated fat: Presumptive evidence for an interaction between vitamins C and E in vivo. Am J Clin Nutr, 67, 240-245.
57. Hayden, K. M., Welsh-Bohmer, K. A., Wengreen, H. J., Zandi, P. P., Lyketsos, C., & Breitner, J. C. (2007). Risk of mortality with vitamin E supplements. The Cache County Study. Am J Med, 120, 180-184.
58. Heart Protection Study Collaborative Group (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7-22.
59. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003). Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol, 60, 1119-1122.
60. Henderson, V., Paganini-Hill, A., Miller, B. L., Elble, R. J., Reyes, P. F., Shoupe, D. et al. (2000). Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology, 54, 295-301.
61. Hendrie, H. C. (1998). Epidemiology of dementia and Alzheimer's disease. Am J Geriatr Psychiatry, 6, S3-18.
62. Hofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van, H. F. et al. (1997). Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet, 349, 151-154.
63. Hogervorst, E., Bandelow, S., & Moffat, S. D. (2005). Increasing testosterone levels and effects on cognitive functions in elderly men and women: A review. Curr Drug Targets CNS Neurol Disord, 4, 531-540.
64. Homocysteine Lowering Trialists' Collaboration (1998). Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ, 316, 894-898.
65. Howard, B. V., Van, H. L., Hsia, J., Manson, J. E., Stefanick, M. L., Wassertheil-Smoller, S. et al. (2006). Low-fat dietary pattern and risk of cardiovascular disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA, 295, 655-666.
66. Huang, T. L., Zandi, P. P., Tucker, K. L., Fitzpatrick, A. L., Kuller, L. H., Fried, L. et al. (2005). Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology, 65, 1409-1414.
67. In 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T. et al. (2001). Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med, 345, 1515-1521.
68. In't Veld, B. A., Ruitenberg, A., Hofman, A., Stricker, B. H., & Breteler, M. M. (2001). Antihypertensive drugs and incidence of dementia: The Rotterdam study. Neurobiol Aging, 22, 407-412.
69. Jama, J. W., Launer, L. J., Witteman, J. C., den Breeijen, J. H., Breteler, M. M., Grobbee, D. E. et al. (1996). Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam study. Am J Epidemiol, 144, 275-280.
70. Jiang, Q., Lykkesfeldt, J., Shigenaga, M. K., Shigeno, E. T., Christen, S., & Ames, B. N. (2002). Gamma-tocopherol supplementation inhibits protein nitration and ascorbate oxidation in rats with inflammation. Free Radic Biol Med, 33, 1534-1542.
71. Kawas, C., Resnick, S., Morrison, A., Brookmeyer, R., Corrada, M., Zonderman, A. et al. (1997). A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology, 48, 1517-1521.
72. Kawas, C. H. (2006). Diet and the risk for Alzheimer's disease. Ann Neurol, 59, 877-879.
73. Khachaturian, A. S., Zandi, P. P., Lyketsos, C. G., Hayden, K. M., Skoog, I., Norton, M. C. et al. (2006). Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch Neurol, 63, 686-692.
74. Kivipelto, M., Helkala, E. L., Laakso, M. P., Hanninen, T., Hallikainen, M., Alhainen, K. et al. (2001). Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ, 322, 1447-1451.
75. Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kareholt, I., Winblad, B. et al. (2005). Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol, 62, 1556-1560.
76. Kleijnen, J., & Knipschild, P. (1992). Ginkgo biloba for cerebral insufficiency. British Journal of Clinical Pharmacology, 34, 352-358.
77. La, R. A., Koehler, K. M., Wayne, S. J., Chiulli, S. J., Haaland, K. Y., & Garry, P. J. (1997). Nutritional status and cognitive functioning in a normally aging sample: A 6-year reassessment. Am J Clin Nutr, 65, 20-29.
78. Launer, L. J. (2002). Demonstrating the case that AD is a vascular disease: Epidemiologic evidence. Ageing Res Rev, 1, 61-77.
79. Lazarov, O., Robinson, J., Tang, Y. P., Hairston, I. S., Korade-Mirnics, Z., Lee, V. M. et al. (2005). Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell, 120, 701-713.
80. Le Bars, P. L., Katz, M. M., Berman, N., Itil, T. M., Freedman, A. M., & Schatzberg, A. F. (1997). A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA, 278, 1327-1332.
81. Li, G., Higdon, R., Kukull, W. A., Peskind, E., Van Valen, M. K., Tsuang, D. et al. (2004). Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. Neurology, 63, 1624-1628.
82. Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001). The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci, 21, 8370-8377.
83. Lindsay, J., Laurin, D., Verreault, R., Hebert, R., Helliwell, B., Hill, G. B. et al. (2002). Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol, 156, 445-453.
84. Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B. et al. (2003). The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens, 21, 875-886.
85. Luchsinger, J. A., Tang, M. X., Shea, S., & Mayeux, R. (2003). Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol, 60, 203-208.
86. Luchsinger, J. A., Tang, M. X., Shea, S., & Mayeux, R. (2004). Hyperinsulinemia and risk of Alzheimer disease. Neurology, 63, 1187-1192.
87. Martin, B. K., Meinert, C. L., & Breitner, J. C. (2002). Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials, 23, 93-99.
88. Masaki, K. H., Losonczy, K. G., Izmirlian, G., Foley, D. J., Ross, G. W., Petrovitch, H. et al. (2000). Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology, 54, 1265-1272.
89. McCaddon, A., Davies, G., Hudson, P., Tandy, S., & Cattell, H. (1998). Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry, 13, 235-239.
90. McGeer, P. L., McGeer, E., Rogers, J., & Sibley, J. (1990). Anti-inflammatory drugs and Alzheimer disease. Lancet, 335, 1037.
91. Meade, E. A., Smith, W. L., & Dewitt, D. L. (1993). Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J Biol Chem, 268, 6610-6614.
92. Mendelsohn, A. B., Belle, S. H., Stoehr, G. P., & Ganguli, M. (1998). Use of antioxidant supplements and its association with cognitive function in a rural elderly cohort: The MoVIES project. Monongahela Valley Independent Elders Survey. Am J Epidemiol, 148, 38-44.
93. Miller III, E. R. III, Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005). Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med, 142, 37-46.
94. Moffat, S. D., Zonderman, A. B., Metter, E. J., Kawas, C., Blackman, M. R., Harman, S. M. et al. (2004). Free testosterone and risk for Alzheimer disease in older men. Neurology, 62, 188-193.
95. Molloy, A. M., & Scott, J. M. (2001). Folates and prevention of disease. Public Health Nutrition, 4, 601-609.
96. Mori, T., Town, T., Tan, J., Yada, N., Horikoshi, Y., Yamamoto, J. et al. (2006). Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J Pharmacol Exp Ther, 318, 571-578.
97. Morris, M. C., Beckett, L. A., Scherr, P. A., Hebert, L. E., Bennett, D. A., Field, T. S. et al. (1998). Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord, 12, 121-126.
98. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Aggarwal, N. et al. (2002). Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA, 287, 3230-3237.
99. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S. et al. (2003). Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol, 60, 940-946.
100. Morris, M. C., Evans, D. A., Schneider, J. A., Tangney, C. C., Bienias, J. L., & Aggarwal, N. T. (2006). Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. J Alzheimers Dis, 9, 435-443.
101. Mulnard, R. A., Cotman, C. W., Kawas, C., van Dyck, C. H., Sano, M., Doody, R. et al. (2000). Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA, 283, 1007-1015.
102. Ng, T. P., Chiam, P. C., Lee, T., Chua, H. C., Lim, L., & Kua, E. H. (2006). Curry consumption and cognitive function in the elderly. Am J Epidemiol, 164, 898-906.
103. Oken, B. S., Storzbach, D. M., & Kaye, J. A. (1998). The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol, 55, 1409-1415.
104. Orgogozo, J. M., Dartigues, J. F., Lafont, S., Letenneur, L., Commenges, D., Salamon, R. et al. (1997). Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. Rev Neurol (Paris), 153, 185-192.
105. Orgogozo, J. M., Gilman, S., Dartigues, J. F., Laurent, B., Puel, M., Kirby, L. C. et al. (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 61, 46-54.
106. Paleologos, M., Cumming, R. G., & Lazarus, R. (1998). Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol, 148, 45-50.
107. Panza, F., Solfrizzi, V., Colacicco, A. M., D'Introno, A., Capurso, C., Torres, F. et al. (2004). Mediterranean diet and cognitive decline. Public Health Nutrition, 7, 959-963.
108. Peila, R., Rodriguez, B. L., & Launer, L. J. (2002). Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes, 51, 1256-1262.
109. Perrig, W. J., Perrig, P., & Stahelin, H. B. (1997). The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc, 45, 718-724.
110. Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S. et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med, 352, 2379-2388.
111. Podewils, L. J., Guallar, E., Kuller, L. H., Fried, L. P., Lopez, O. L., Carlson, M. et al. (2005). Physical activity, APOE genotype, and dementia risk: Findings from the Cardiovascular Health Cognition Study. Am J Epidemiol, 161, 639-651.
112. Prince, M., Lewis, G., Bird, A., Blizard, R., & Mann, A. (1996). A longitudinal study of factors predicting change in cognitive test scores over time, in an older hypertensive population. Psychol Med, 26, 555-568.
113. Razay, G., Vreugdenhil, A., & Wilcock, G. (2006). Obesity, abdominal obesity and Alzheimer disease. Dement Geriatr Cogn Disord, 22, 173-176.
114. Rea, T. D., Breitner, J. C., Psaty, B. M., Fitzpatrick, A., Lopez, O. L., Newman, A. et al. (2005). Statin use and the risk of incident dementia: The Cardiovascular Health Study. Arch Neurol, 62, 1047-1051.
115. Refolo, L. M., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S. et al. (2000). Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis, 7, 321-331.
116. Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R. et al. (2004). Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology, 62, 66-71.
117. Reitz, C., Tang, M. X., Luchsinger, J., & Mayeux, R. (2004). Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol, 61, 705-714.
118. Risner, M. E., Saunders, A. M., Altman, J. F., Ormandy, G. C., Craft, S., Foley, I. M. et al. (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J, 6, 246-254.
119. Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R. et al. (2002). Use of lipid-lowering agents, indication bias, and the risk of dementia in communitydwelling elderly people. Arch Neurol, 59, 223-227.
120. Rodriguez, E. G., Dodge, H. H., Birzescu, M. A., Stoehr, G. P., & Ganguli, M. (2002). Use of lipid-lowering drugs in older adults with and without dementia: A community-based epidemiological study. J Am Geriatr Soc, 50, 1852-1856.
121. Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W. et al. (1993). Clinical trial of indomethacin in Alzheimer's disease. Neurology, 43, 1609-1611.
122. Rovio, S., Kareholt, I., Helkala, E. L., Viitanen, M., Winblad, B., Tuomilehto, J. et al. (2005). Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neuro, 4, 705-711.
123. Sadowski, M., Pankiewicz, J., Scholtzova, H., Li, Y. S., Quartermain, D., Duff, K. et al. (2004). Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res, 29, 1257-1266.
124. Sainati, S., Ingram, D., Talwalker, S., & Geis, G. (2000). Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's Disease. In 6th International Stockholm-Springfield Symposium of Advances in Alzheimer's Therapy; Stockholm, Sweden.
125. Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M. et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med, 336, 1216-1222.
126. Santanello, N. C., Barber, B. L., Applegate, W. B., Elam, J., Curtis, C., Hunninghake, D. B. et al. (1997). Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc, 45, 8-14.
127. Scarmeas, N., Stern, Y., Tang, M. X., Mayeux, R., & Luchsinger, J. A. (2006). Mediterranean diet and risk for Alzheimer's disease. Ann Neurol, 59, 912-921.
128. Schaefer, E. J., Bongard, V., Beiser, A. S., Lamon-Fava, S., Robins, S. J., Au, R. et al. (2006). Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham heart study. Arch Neurol, 63, 1545-1550.
129. Scharf, S., Mander, A., Ugoni, A., Vajda, F., & Christophidis, N. (1999). A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology, 53, 197-201.
130. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T. et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177.
131. Schneider, L. S., DeKosky, S. T., Farlow, M. R., Tariot, P. N., Hoerr, R., & Kieser, M. (2005). A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res, 2, 541-551.
132. Selhub, J., Jacques, P. F., Bostom, A. G., D'Agostino, R. B., Wilson, P. W., Belanger, A. J. et al. (1995). Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med, 332, 286-291.
133. Selkoe, D. J. (2004). Alzheimer disease: Mechanistic understanding predicts novel therapies. Ann Intern Med, 20, 140, 627-638.
134. Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B. et al. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med, 346, 476-483.
135. SHEP Cooperative Research Group (1991). Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 265, 3255-3264.
136. Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M. et al. (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet, 360, 1623-1630.
137. Shumaker, S. A., Legault, C., & Coker, L. H. (2006). Behavior-based interventions to enhance cognitive functioning and independence in older adults. JAMA, 296, 2852-2854.
138. Shumaker, S. A., Legault, C., Kuller, L., Rapp, S. R., Thal, L., Lane, D. S. et al. (2004). Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA, 291, 2947-2958.
139. Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K. et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA, 289, 2651-2662.
140. Skoog, I., & Gustafson, D. (1999). HRT and dementia. J Epidemiol Biostat, 4, 227-251.
141. Skoog, I., & Gustafson, D. (2006). Update on hypertension and Alzheimer's disease. Neurol Res, 28, 605-611.
142. Snowdon, D. A., Greiner, L. H., Mortimer, J. A., Riley, K. P., Greiner, P. A., & Markesbery, W. R. (1997). Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA, 277, 813-817.
143. Solomon, S. D., McMurray, J. J., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P. et al. (2005). Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med, 352, 1071-1080.
144. Sparks, D. L., Sabbagh, M., Connor, D., Soares, H., Lopez, J., Stankovic, G. et al. (2006). Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl, 185, 78-86.
145. Stern, Y. (2006). Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord, 20, S69-S74.
146. Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology, 48, 626-632.
147. Szekely, C. A., Breitner, J. C., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H. et al. (in press). NSAID use and dementia risk in the Cardiovascular Health Study: Role of APOE and NSAID type. Neurology, Epub ahead of print.
148. Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. et al. (2004). Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review. Neuroepidemiology, 23, 159-169.
149. Szekely, C. A., Town, T., & Zandi, P. P. (2007). NSAIDs for the chemoprevention of Alzheimer's disease. In R. E. Harris (Ed.), Inflammation in the Pathogenesis of Chronic Diseases: The COX-2 controversy. Biomedical series. Chapter 11, Volume 42. Dordrecht, The Netherlands: Springer.
150. Tang, M. X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B. et al. (1996). Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet, 348, 429-432.
151. Thal, L. J. (2006). Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord, 20, S97-S99.
152. Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E. et al. (2005). A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology, 30, 1204-1215.
153. Tzourio, C., Anderson, C., Chapman, N., Woodward, M., Neal, B., MacMahon, S. et al. (2003). Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med, 163, 1069-1075.
154. US Census Bureau. (2004). Annual projections of the resident population by age, sex, race, and hispanic origin: Lowest, middle, highest series and zero international migration series, 1999 to 2100.
155. Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 231, 232-235.
156. Vanhanen, M., Koivisto, K., Moilanen, L., Helkala, E. L., Hanninen, T., Soininen, H. et al. (2006). Association of metabolic syndrome with Alzheimer disease: A population-based study. Neurology, 67, 843-847.
157. Vellas, B., Andrieu, S., Ousset, P. J., Ouzid, M., & Mathiex-Fortunet, H. (2006). The GuidAge study: Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761(R) for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology, 67, S6-S11.
158. Wang, P. N., Liao, S. Q., Liu, R. S., Liu, C. Y., Chao, H. T., Lu, S. R. et al. (2000). Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study. Neurology, 54, 2061-2066.
159. Wang, R., & Tang, X. C. (2005). Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals, 14, 71-82.
160. Wang, R., Yan, H., & Tang, X. C. (2006). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin, 27, 1-26.
161. Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S. et al. (2005). Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry, 13, 950-958.
162. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U. et al. (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently
163. Weiner, H. L., & Frenkel, D. (2006). Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol, 6, 404-416.
164. White, A. R., Huang, X., Jobling, M. F., Barrow, C. J., Beyreuther, K., Masters, C. L. et al. (2001). Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: Possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem, 76, 1509-1520.
165. Willis, S. L., Tennstedt, S. L., Marsiske, M., Ball, K., Elias, J., Koepke, K. M. et al. (2006). Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA, 296, 2805-2814.
166. Wolkowitz, O. M., Kramer, J. H., Reus, V. I., Costa, M. M., Yaffe, K., Walton, P. et al. (2003). DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study. Neurology, 60, 1071-1076.
167. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., & Siegel, G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol, 57, 1439-1443.
168. Yaffe, K., Krueger, K., Cummings, S. R., Blackwell, T., Henderson, V. W., Sarkar, S. et al. (2005). Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry, 162, 683-690.
169. Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S. et al. (2005). Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem, 280, 5892-5901.
170. Yip, A. G., Green, R. C., Huyck, M., Cupples, L. A., & Farrer, L. A. (2005). Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: The MIRAGE Study. BMC.Geriatr., 5, 2.
171. Yki-Jarvinen, H. (2004). Thiazolidinediones. N Engl J Med, 351, 1106-1118.
172. Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K. et al. (1995). Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology, 45, 1161-1168.
173. Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K., Mayer, L., & Breitner, J. C. (2002a). Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology, 59, 880-886.
174. Zandi, P. P., Anthony, J. C., Khachaturian, A. S., Stone, S. V., Gustafson, D., Tschanz, J. T. et al. (2004). Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol, 61, 82-88.
175. Zandi, P. P., Carlson, M. C., Plassman, B. L., Welsh-Bohmer, K. A., Mayer, L. S., Steffens, D. C. et al. (2002b). Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA, 288, 2123-2129.
176. Zandi, P. P., Sparks, D. L., Khachaturian, A. S., Tschanz, J., Norton, M., Steinberg, M. et al. (2005). Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry, 62, 217-224.